A retrospective study on the safety and efficacy of ramucirumab administered as a single agent in subjects with gastric or gastroesophageal junction adenocarcinoma.
Phase of Trial: Phase IV
Latest Information Update: 05 Apr 2016
At a glance
- Drugs Ramucirumab (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Adverse reactions; Therapeutic Use
- 05 Apr 2016 New trial record